Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

From Strength to Strength: Unpacking Clinigen's Ro...

Putting patient care at the heart of its mission, Clinigen’s unique approac...

Read More

[Webinar Recording] The Current State of the M&A L...

Are you considering M&A transactions as a potential exit strategy, step to ...

Read More

[Webinar Recording] The Anatomy of a successful IP...

On the 27th June, we spoke to an expert panel to discuss the how, when, wha...

Read More

Will Horizon successfully navigate the path to pro...

Currently one of the most successful life science companies in the country,...

Read More

Management to investors: the communicative conundr...

We have published our annual investor perception survey, confirming or disp...

Read More

All in the Delivery - Interview with Simon Newman,...

Biotech and Money recently talked to Simon Newman, CSO of Ryboquin, about t...

Read More

Interview with Daniel Oliver, CEO of Capital Cell

Daniel Oliver, CEO of Capital Cell, recently took the time to grant us an i...

Read More

Patenting problems specific to the biotech and hea...

This is the fourth and final article in our series that aims to provide tip...

Read More

Nine things we learned from Centauri CEO Mike West...

Biotech and Money recently talked to Mike Westby, CEO of Centauri, about th...

Read More

Interview with Dr Sara Nunez-Garcia, Principal, So...

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

Read More

What are the most important lessons to be learnt f...

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

Read More

Bionure breaks the records raising more than 1M€

Highlights Capital Cell’s crowdfunding campaign - Bionure - overfunds with ...

Read More
  • Prev

Add Your Response